Longport, Inc. Announces Sale of Scanners to National Long Term Care Group

  
    
  
  
    
      Longport, Inc. (OTC PK:LPTI), a medical technology specialist in high 
      frequency high resolution ultrasound imaging, today announced the sale 
      of thirteen (13) EPISCAN units to a commercial operator of senior care 
      facilities. These EPISCAN units are going to be used for the early 
      detection, documentation, and prevention of pressure ulcers in the group’s 
      skilled nursing facilities.
    
    
      Longport has been conducting a study with the purchasing group for the 
      last two years, and the impressive results have led them to make this 
      purchase. The study was conducted in three Montana nursing homes. The 
      principal investigator of this study, Dr. Karen Zulkowski, explored the 
      use of Longport’s EPISCAN I-200 for improved 
      clinical detection of pressure ulcer risk and development. Dr. Zulkowski 
      is a professor of nursing at Montana State University-Bozeman. 
      Provisional results from the study were presented at the 2007 Symposium 
      on Advanced Wound Care and at a workshop held as part of the Advances in 
      Skin and Wound Care Conference in October 2007.
    
    
      Dr. Zulkowski said “Study results demonstrated 
      that 90% of people come into a nursing home with deep tissue skin 
      changes at their heels and 60% have deep tissue changes at their sacrum. 
      The EPISCAN I-200 shows these changes even before they are visible at 
      the skin surface. This technology will allow the facilities to begin 
      care planning earlier and increase quality of care for their residents. 
      I hope all levels of care including acute care and rehabilitation 
      facilities will also adopt the technology so that risk assessment is 
      comprehensive and prevention is started earlier and is individualized to 
      meet each patient’s needs.”
    
    
      The EPISCAN will be used as part of the facilities’ 
      admission process and for regular ongoing skin assessment protocols. 
      Installation of the units is expected to commence in approximately one 
      month.
    
    
      Paul Wilson, President of Longport, Inc. said “We 
      are pleased to report the order is a direct result of the positive 
      feedback received from the study sites where the EPISCAN has been in use 
      for the last two years. With this sale, Longport has sold a total of 
      twenty (20) units so far this year. The first quarter of 2008 has been 
      extremely promising and we are confident that sales will continue to 
      grow as the year progresses.”
    
    
      About Longport, Inc.
    
    
      Longport, Inc. of Glen Mills, Pennsylvania, is a medical technology 
      company that specializes in high resolution ultrasound imaging. After 
      several years and a multi-million dollar investment in the technology, 
      Longport has secured patents, copyrights, and FDA permission to market. 
      The Company’s technology has been used to 
      engineer a unique high resolution ultrasound imaging system. For further 
      information please contact Longport, Inc. at 1-800-289-6863 or visit our 
      website at www.longportinc.com.
    
    
      Forward-looking Information and the 
      Private Securities Litigation Reform Act of 1995
    
    
      Certain statements in this press release, including statements 
      concerning product development milestones and anticipated events, are “forward-looking 
      statements” within the Private Litigation 
      Reform Act of 1995. Forward Looking Statements are based on the opinions 
      and estimates of management at the time the statements are made and are 
      subject to certain risks and uncertainties that could cause actual 
      results to differ materially from those anticipated in the 
      forward-looking statements. The words “believe,” 
      “expect,” ”intend,” 
      “anticipate,” 
      variations of such words, and similar expressions identify 
      forward-looking statements, but their absence does not mean that the 
      statement is not forward-looking. These statements are not guarantees of 
      future performance and are subject to certain risks, uncertainties and 
      assumptions that are difficult to predict. Factors that could affect 
      Longport’s actual results include, among 
      others, uncertainties as to the Company’s 
      ability to manage potential problems, delays or anticipated expenses, 
      including problems, delays or expenses involving manufacturing. Readers 
      are cautioned not to place undue reliance upon these forward-looking 
      statements that speak only to the date of this release. Reference is 
      made to Longport’s 2004 annual report on Form 
      10-K filed with the Securities and Exchange Commission for a more 
      definitive description of such factors. Longport, Inc. undertakes no 
      obligation to update publicly any forward-looking statements to reflect 
      new information, events or circumstances after the date of this release 
      or to reflect the occurrence of unanticipated events.